MedTrace Logo

An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063

NCT02370602 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2026-05-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to estimate phosphodiesterase 10A (PDE10A) occupancy in brain following a single dose of TAK-063.

Conditions

  • Healthy Volunteers

Interventions

DRUG

TAK-063

TAK-063 tablets

DRUG

[^11C]T-773

\[\^11C\]T-773 IV solution

Sponsors & Collaborators

Principal Investigators

  • Medical Director Clinical Science · Takeda (Note: This product was divested to Axsome in 2026)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-02-28
Completion
2014-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02370602 on ClinicalTrials.gov